ESMO 2025: enhertu shows highest pCR rate in HER2+ early breast cancer

Daiichi Sankyo and AstraZeneca reported significant Phase 3 results for ENHERTU (trastuzumab deruxtecan) in high-risk, HER2 positive early-stage breast cancer, demonstrating an 11.2% improvement in pathologic complete response rate (67.3% vs 56.3%) with a favorable safety profile, leading to a supplemental Biologics License Application under FDA review. Further data showed a 92.4% invasive disease-free survival rate over three years, positioning ENHERTU as a potential foundational therapy. This clinical success aligns with Daiichi Sankyo's robust financial health, featuring a 78.5% gross profit margin and 14% revenue growth, with InvestingPro analysis suggesting the stock is currently undervalued, while the companies also advanced other oncology pipeline assets like DATROWAY and raludotatug deruxtecan.

Analysis

Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a statistically significant 11.2% improvement in pathologic complete response (pCR) rate, achieving 67.3% versus 56.3% for standard treatment, in the Phase 3 DESTINY-Breast11 trial for high-risk HER2 positive early-stage breast cancer. This efficacy, coupled with a favorable safety profile (37.5% vs 55.8% grade 3+ adverse events), supports its potential as a foundational treatment. A supplemental Biologics License Application (sBLA) based on these results is currently under FDA review, indicating near-term regulatory catalysts.

Further data highlighted ENHERTU's long-term benefit with a 92.4% invasive disease-free survival rate over three years and a 53% risk reduction compared to trastuzumab emtansine. Beyond ENHERTU, both companies are advancing other oncology assets, including DATROWAY for urothelial and triple-negative breast cancer, and raludotatug deruxtecan (with Merck) receiving FDA Breakthrough Therapy Designation. Daiichi Sankyo specifically exhibits strong commercial execution with a 78.5% gross profit margin and 14% revenue growth over the last twelve months.

The strongly positive sentiment (0.85) and significant market impact (0.75) reflect the importance of these clinical advancements, particularly for AstraZeneca (0.9 sentiment) and Daiichi Sankyo. InvestingPro analysis suggests Daiichi Sankyo's stock is currently trading below its Fair Value, potentially offering an attractive entry point given the robust pipeline progress and solid financial metrics. The broad oncology pipeline developments underscore sustained growth potential in the high-value cancer treatment market.

Key Decisions for Investors

• Investors should evaluate the long-term growth prospects for AstraZeneca and Daiichi Sankyo, given the robust clinical success of ENHERTU and the breadth of their oncology pipelines.
• Monitor the FDA's decision on ENHERTU's supplemental Biologics License Application, as approval would significantly expand its market potential and reinforce its foundational role in early breast cancer treatment.
• Consider a deeper dive into Daiichi Sankyo's valuation, as InvestingPro analysis suggests it may be trading below its fair value, presenting a potential opportunity supported by strong financials and pipeline momentum.